ArticleOncogene2006
Upregulation of BAK by butyrate in the colon is associated with increased Sp3 binding.
Article in Oncogene, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 70 citations in OpenAlex.
- Trial
- Article
- Eating away cancer: the potential of diet and the microbiome for shaping immunotherapy outcome.Frontiers in immunology · 2024Review
- Beneficial insights into postbiotics against colorectal cancer.Frontiers in nutrition · 2023Review
- Tumor microbiome metabolism: A game changer in cancer development and therapy.Frontiers in oncology · 2022Review
- Homocysteine-induced decrease in HUVEC cells' resistance to oxidative stress is mediated by Akt-dependent changes in iron metabolism.European journal of nutrition · 2021Article
- Postbiotics, Metabolic Signaling, and Cancer.Molecules (Basel, Switzerland) · 2021Review
- Gut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer.Nature reviews. Gastroenterology & hepatology · 2018Review
- Histone deacetylase inhibitors induce the expression of tumor suppressor genes Per1 and Per2 in human gastric cancer cells.Oncology letters · 2018Article
- Article
- Article
- ATF3 Repression of BCL-XClinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Is cytotoxicity a determinant of the different in vitro and in vivo effects of bioactives?BMC complementary and alternative medicine · 2017Article
- SP and KLF Transcription Factors in Digestive Physiology and Diseases.Gastroenterology · 2017Review
- Diet, microorganisms and their metabolites, and colon cancer.Nature reviews. Gastroenterology & hepatology · 2016Review
- Physiological TLR5 expression in the intestine is regulated by differential DNA binding of Sp1/Sp3 through simultaneous Sp1 dephosphorylation and Sp3 phosphorylation by two different PKC isoforms.Nucleic acids research · 2016Article
- Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells.Antioxidants & redox signaling · 2015Review
- Inflammaging and cancer: a challenge for the Mediterranean diet.Nutrients · 2015Review
- Reduced keratin expression in colorectal neoplasia and associated fields is reversible by diet and resection.BMJ open gastroenterology · 2015Article
- Three measurable and modifiable enteric microbial biotransformations relevant to cancer prevention and treatment.Global advances in health and medicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Butyrate is a key bioactive product of dietary fibre fermentation thought to play a key role in cancer prevention. One contributory mechanism in this role is the regulation of apoptosis by butyrate. As butyrate shows low levels of toxicity, the mechanisms by which it triggers or regulates apoptosis are of great interest. We and others have shown that the proapoptotic protein BAK is upregulated by butyrate. We show here that this observation is conserved across multiple cell lines, that it occurs in all cells in a population and is at the transcriptional level. We have used a promoter-reporter construct to identify the regulatory regions of the BAK promoter and found that much of the transcriptional activity occurs via a single Sp1/Sp3 binding site. We have shown that both Sp1 and Sp3 bind, but upon butyrate treatment Sp1 binding decreases in favour of Sp3 binding. We speculate that this may be an acetylation-mediated event.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.